124 related articles for article (PubMed ID: 26021284)
1. Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
Mocikova H; Pytlik R; Stepankova P; Michalka J; Markova J; Koren J; Buresova L; Raida L; Kral Z
Acta Haematol; 2015; 134(3):187-92. PubMed ID: 26021284
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
3. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
[TBL] [Abstract][Full Text] [Related]
4. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
5. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
6. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.
Advani RH; Horning SJ; Hoppe RT; Daadi S; Allen J; Natkunam Y; Bartlett NL
J Clin Oncol; 2014 Mar; 32(9):912-8. PubMed ID: 24516013
[TBL] [Abstract][Full Text] [Related]
7. Nodular lymphocyte predominant Hodgkin's lymphoma.
Siddiqui N; Al-Diab AI
Saudi Med J; 2005 Feb; 26(2):241-5. PubMed ID: 15770298
[TBL] [Abstract][Full Text] [Related]
8. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
Maeda LS; Advani RH
Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.
Eichenauer DA; Fuchs M; Pluetschow A; Klimm B; Halbsguth T; Böll B; von Tresckow B; Nogová L; Borchmann P; Engert A
Blood; 2011 Oct; 118(16):4363-5. PubMed ID: 21828141
[TBL] [Abstract][Full Text] [Related]
10. Nodular lymphocyte-predominant Hodgkin lymphoma.
Fuchs M; Eichenauer DA; Nogová L; Diehl V; Engert A;
Curr Hematol Malig Rep; 2008 Jul; 3(3):126-31. PubMed ID: 20425457
[TBL] [Abstract][Full Text] [Related]
11. Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma.
Galán L; Sánchez AC; Cantos B; Provencio M
Clin Transl Oncol; 2010 May; 12(5):384-6. PubMed ID: 20466624
[TBL] [Abstract][Full Text] [Related]
12. Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience.
Gemici A; Aydogdu I; Terzi H; Sencan M; Aslan A; Kaya AH; Dal MS; Akay MO; Dogu MH; Ayyildiz O; Sahin F; Cagliyan GA; Yilmaz M; Gokgoz Z; Bilen Y; Demir C; Sevindik OG; Korkmaz S; Eser B; Altuntas F;
Hematol Oncol; 2018 Feb; 36(1):116-120. PubMed ID: 28707314
[TBL] [Abstract][Full Text] [Related]
13. Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.
Lazarovici J; Dartigues P; Brice P; Obéric L; Gaillard I; Hunault-Berger M; Broussais-Guillaumot F; Gyan E; Bologna S; Nicolas-Virelizier E; Touati M; Casasnovas O; Delarue R; Orsini-Piocelle F; Stamatoullas A; Gabarre J; Fornecker LM; Gastinne T; Peyrade F; Roland V; Bachy E; André M; Mounier N; Fermé C
Haematologica; 2015 Dec; 100(12):1579-86. PubMed ID: 26430172
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; von Tresckow B; Böll B; Behringer K; Diehl V; Eich HT; Borchmann P; Engert A
J Clin Oncol; 2015 Sep; 33(26):2857-62. PubMed ID: 26240235
[TBL] [Abstract][Full Text] [Related]
15. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Schröder L; Fuchs M; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
Blood; 2018 Oct; 132(14):1519-1525. PubMed ID: 30064977
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of 2 patients treated with
Golstein SC; Muylle K; Vercruyssen M; Spilleboudt C; de Wind A; Bron D
Eur J Haematol; 2018 Sep; 101(3):415-417. PubMed ID: 29719928
[TBL] [Abstract][Full Text] [Related]
17. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients.
Brice P; Bastion Y; Divine M; Nedellec G; Ferrant A; Gabarre J; Reman O; Lepage E; Fermé C
Cancer; 1996 Sep; 78(6):1293-9. PubMed ID: 8826953
[TBL] [Abstract][Full Text] [Related]
18. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
[TBL] [Abstract][Full Text] [Related]
19. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
Pijuan L; Vicioso L; Bellosillo B; Ferrer MD; Baró T; Pedro C; Lloreta-Trull J; Munné A; Serrano S
Am J Surg Pathol; 2005 Oct; 29(10):1399-403. PubMed ID: 16160485
[TBL] [Abstract][Full Text] [Related]
20. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]